Categories: Health

Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CHASKA, Minn., Jan. 16, 2026 (GLOBE NEWSWIRE) — Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated contract development and manufacturing organization (“CDMO”), today announced that on January 14, 2026, the Lifecore compensation committee approved grants under Lifecore’s Equity Inducement Plan, as amended (the “Inducement Plan”) of restricted stock unit (“RSU”) awards with respect to an aggregate 1,738 shares of its common stock and stock options for an aggregate 8,775 shares of common stock to two newly hired employees of Lifecore. The RSU award and stock options were granted on January 14, 2026, pursuant to the offer letters between Lifecore and each employee, and as a material inducement to each employee joining Lifecore.

The RSU awards and stock options were approved by Lifecore’s compensation committee and were granted as inducement equity awards in accordance with Nasdaq Listing Rule 5635(c)(4) under the Inducement Plan.

The RSUs will vest and be settled on the third anniversary of the grant date, subject to continued employment. The stock options have an exercise price equal to Fair Market Value (as defined in the Inducement Plan) on the grant date and will vest as to one-third of the shares on the first anniversary of the grant date and as to 1/36th of the shares on each monthly grant date thereafter, subject to continued employment. The stock options have a seven-year term. The RSU award and stock options are each governed by an award agreement and the Inducement Plan.

About Lifecore Biomedical
Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore’s website at www.lifecore.com.



GlobeNews Wire

Recent Posts

iFLYTEK Launches GuideX, Taking Public Services from Answering Questions to Completing Tasks

SHANGHAI, July 18, 2026 (GLOBE NEWSWIRE) -- iFLYTEK launched GuideX on Friday, an intelligent interaction…

6 minutes ago

United Flow Technologies Expands Midwest Presence with Acquisition of Peterson and Matz

July 17, 2026 18:30 ET  | Source: United Flow Technologies Irving, TX, July 17, 2026…

6 minutes ago

MKDWELL Tech Inc. to Acquire Premium Smart-Home and IoT Group, Diversifying Beyond Automotive Electronics

Hsinchu, Taiwan, July 17, 2026 (GLOBE NEWSWIRE) -- MKDWELL Tech Inc. (“MKDWELL” or the “Company”)…

6 minutes ago

Farizon Opens Global Spare Part Distribution Center to Strengthen International Aftersales Support

New facility will improve parts availability, supply-chain efficiency and service responsiveness across Farizon's international marketsHANGZHOU,…

3 hours ago

Global Commercial Service Robot Shipments Leader KEENON Puts Humanoids to Work at WAIC 2026

SHANGHAI, July 17, 2026 /PRNewswire/ -- At WAIC 2026, KEENON Robotics is bringing humanoid and specialized…

8 hours ago

e& Successfully Completes Sale of Vodafone Stake, Realizing Cash Proceeds of USD 5.95 Billion

ABU DHABI, UAE, July 17, 2026 /PRNewswire/ -- Further to Emirates Telecommunications Group Company PJSC…

10 hours ago